Cargando…

Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients

INTRODUCTION: Several genetic single nucleotide polymorphisms (SNPs) in biotransformation enzymes (CYP3A4, CYP3A5) or transporter proteins (multidrug resistance MDR1 gene product, P-gp) are involved in PI metabolism so that PI pharmacokinetics is characterized by a large inter-individual variability...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berno, Giulia, Zaccarelli, Mauro, Gori, Caterina, Tempestilli, Massimo, Pucci, Luigia, Antinori, Andrea, Perno, Carlo Federico, Paolo Pucillo, Leopoldo, D'Arrigo, Roberta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P057
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224892/ https://www.ncbi.nlm.nih.gov/pubmed/25394094 http://dx.doi.org/10.7448/IAS.17.4.19589

Ejemplares similares

Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs
por: Berno, Giulia, et al.
Publicado: (2014)

Virtual exercise in response to the Covid-19 pandemic in people with cystic fibrosis
por: Gyte, R., et al.
Publicado: (2022)

Outcomes related to 4864 pregnancies with exposure to lopinavir/ritonavir (LPV/r)
por: Tookey, Pat, et al.
Publicado: (2014)

144-week outcomes of lopinavir/ritonavir (LPV/r)-based first-line ART in 1,409 HIV-infected patients: data from the German STAR/STELLA cohort
por: Wolf, Eva, et al.
Publicado: (2014)

CHOQUE HIPOVOLÊMICO POR FÍSTULA TRAQUEIA ‐ TRONCO BRAQUIOENCEFÁLICO EM PACIENTE JOVEM COM COVID 19 EVOLUÇÃO COM PARADA CARDIORRESPIRATÓRIA DE 53 MINUTOS SEM SEQUELAS
por: Ferreira, Gisele Maria, et al.
Publicado: (2021)

Une apoplexie d’un adénome hypophysaire au cours d’une infection COVID-19 : quel lien ?
por: Outili, I., et al.
Publicado: (2021)

FATORES PREDITORES DO DIAGNÓSTICO DE COVID-19 EM INDIVÍDUOS AVALIADOS NA ATENÇÃO PRIMÁRIA À SAÚDE DE FORTALEZA - DADOS PRELIMINARES
por: Guimarães, Roseline Carvalho, et al.
Publicado: (2022)

PERFIL EPIDEMIOLÓGICO DOS ÓBITOS OCASIONADOS POR COVID-19 NO MUNICÍPIO DE REDENÇÃO,PA
por: Lustosa, Fabricia Dutra Dantas, et al.
Publicado: (2022)

Les virus SARS-COV-2 et HHV-8 repérés ensemble
por: Said El Mabrouk, R., et al.
Publicado: (2022)

Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication
por: Pinnetti, Carmela, et al.
Publicado: (2014)

Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1
por: Maroldo, L, et al.
Publicado: (2010)

HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2–3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy
por: Martin, Allison, et al.
Publicado: (2013)

Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting
por: Gianotti, Nicola, et al.
Publicado: (2014)

CSF LPV concentrations and viral load in viral suppressed patients on LPV/r monotherapy given once daily
por: Tiraboschi, Juan, et al.
Publicado: (2014)

Inhibition of CYP3A7 DHEA-S Oxidation by Lopinavir and Ritonavir: An Alternative Mechanism for Adrenal Impairment in HIV Antiretroviral-Treated Neonates
por: Kandel, Sylvie E., et al.
Publicado: (2021)

No significant association between patient self-reported non-adherence to antiretrovirals and HIV-tropism: a preliminary analysis
por: Ammassari, A, et al.
Publicado: (2012)

HRQoL improves in treatment-naïve HIV-1 subjects initiated on lopinavir/ritonavir (LPV/r) with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC)
por: Baran, RW, et al.
Publicado: (2010)

Current Efavirenz (EFV) or Ritonavir-Boosted Lopinavir (LPV/r) Use Correlates with Elevate Markers of Atherosclerosis in HIV-Infected Subjects in Addis Ababa, Ethiopia
por: Gleason, Rudolph L., et al.
Publicado: (2015)

A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs. twice daily lopinavir/ritonavir (LPV/r) regimens
por: Qaqish, R, et al.
Publicado: (2010)

ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults
por: Orkin, C, et al.
Publicado: (2010)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

Effect of CYP3A4, CYP3A5, MDR1 and POR Genetic Polymorphisms in Immunosuppressive Treatment in Chilean Kidney Transplanted Patients
por: Contreras-Castillo, Stephania, et al.
Publicado: (2021)

The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?
por: Loos, Nancy H. C., et al.
Publicado: (2022)

Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice
por: Costarelli, Silvia, et al.
Publicado: (2014)

Propofol/lopinavir/ritonavir: Bradyarrythmia: case report
Publicado: (2020)

CYP3A5*3, CYP3A4*1B and MDR1 C3435T Genotype Distributions in Ecuadorians
por: Sinués, Blanca, et al.
Publicado: (2008)

Sildenafil and Bosentan Plasma Concentrations in a Human Immunodeficiency Virus- Infected Patient with Pulmonary Arterial Hypertension Treated with Ritonavir-Boosted Protease Inhibitor
por: Chinello, Pierangelo, et al.
Publicado: (2015)

Biological interactions of CYP2C19 genotypes with CYP3A4*18, CYP3A5*3, and MDR1-3435 in living donor liver transplantation recipients
por: Chiu, King-Wah, et al.
Publicado: (2013)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
por: Ceccaldi, Pierre-François, et al.
Publicado: (2010)

Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
por: Alvarez, Jean Claude, et al.
Publicado: (2020)

Lopinavir/ritonavir: vomiting and watery diarrhoea: case report
Publicado: (2020)

Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients
Publicado: (2020)

Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020)

The administration of lopinavir/ritonavir via an enteral feeding tube()
por: Sirvent Segovia, Alejandro Esteban, et al.
Publicado: (2021)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with LPV/r+3TC for initial ART in HIV infected adults
por: Gatell, Josép M, et al.
Publicado: (2014)

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review
por: Chandwani, Ashish, et al.
Publicado: (2008)

Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
por: Reyskens, Kathleen M. S. E., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_d3p32tic9l4kcvn6t4pqhnr7dp